| Previous Close | 33.32 |
| Open | 33.38 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 33.01 - 33.48 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 19,787,519 |
| Avg. Volume | 20,314,514 |
| Market Cap | 197.54B |
| Beta | 1.07 |
| PE Ratio (TTM) | 27.86 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.82%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Zacks•7 hours ago
Top Analyst Reports for Oracle, Pfizer & Abbott
Top Analyst Reports for Oracle, Pfizer & Abbott
- Reuters•7 hours ago
Adviser charged with insider trading on Pfizer-King deal pleads guilty
A Long Island, New York, investment adviser accused of engaging in insider trading after being tipped off about Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc pleaded guilty on Tuesday, federal prosecutors said. Tibor Klein, 43, pleaded guilty to one count of conspiracy to commit securities fraud before U.S. District Judge Joan Azrack in federal court in Brooklyn, New York.
- Market Realist•14 hours ago
Why Pfizer’s Sutent Could Witness a Modest Decline in 2017
In 2016, Pfizer’s (PFE) Sutent reported revenues of ~$1.1 billion, which represented a ~2% decline on a YoY (year-over-year) basis.
